IL-6, IL-8 and IL-1ra levels during hospitalisation and according to time from symptom onset
ST-elevation myocardial infarction
For IL-6, we observed a substantial increase in the tocilizumab group compared with both baseline and placebo during hospitalisation. A similar pattern was observed for IL-8 and IL-1ra (Mean and 95% CIs for cytokines with a significant group×time interaction after Bonferroni correction (p<0.002) during hospitalisation.The increase in IL-6 in patients treated with tocilizumab was observed regardless of symptom duration, but the increase was more pronounced in the patients presenting >3 hours from symptom onset. For IL-1ra and IL-8, we only observed a significant treatment effect in those with symptom duration ≤3 hours (Multiplex cytokine assay during hospitalisation in patients with ST-elevation myocardial infarction receiving placebo (n=98) and tocilizumab (n=101), stratified by time (≤3 and >3 hours)Data are mean and (95% CI). P value in table are mixed between-within subjects analysis of variance. P values in footnotes are between group differences in changes from baseline, independent sample t-test.*p<0.05.†p<0.01.‡p<0.001.IL-6, interleukin-6; IL-8, interleukin-8; IL-1ra, interleukin-1 receptor antagonist.